Merck and Kelun-Biotech's ADC sac-TMT secures first global Phase 3 win ahead of schedule
read at Endpoints ↗Positive readoutPositive
Merck and China-based Kelun-Biotech reported that their experimental antibody-drug conjugate sac-TMT achieved a positive outcome in a global Phase 3 study, marking the first such success for the candidate.
The result arrived ahead of the planned timeline, delivering a crucial pipeline milestone as Merck approaches the patent cliff for its best-selling medicines.
The win highlights the promise of the ADC platform and could bolster Merck’s oncology portfolio moving forward.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Merck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule”
read at Endpoints ↗84 words · retrieved May 18
comments(0)
5-min edit window · permanent after that